目的 分析肺原发性黏膜相关淋巴组织淋巴瘤的临床特征和预后.方法 回顾分析1999-2012年间14例肺原发性黏膜相关淋巴组织淋巴瘤患者临床资料,其中ⅠE期8例、ⅡE期5例、ⅢE期1例.4例单纯手术治疗,5例术后放疗或化疗,3例化放疗,2例单纯化疗.结果 中位年龄为55岁,男女之比为1∶1.33.中位随访时间为48.3个月.全组患者均存活,3例患者出现治疗失败.全组患者2、4年无进展生存率分别为91％和69％.治疗失败发生在疗后25 ～ 37个月,失败部位为双肺、纵隔淋巴结、右肺和脑膜.结论 肺原发黏膜相关淋巴组织淋巴瘤为惰性淋巴瘤,预后良好;临床上可根据患者病变范围和身体状况选择适当治疗.%Objective To analyze the clinical features and prognosis of patients with primary pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma.Methods A retrospective analysis was performed on the clinical data of 14 patients with primary pulmonary MALT lymphoma between 1999 and 2012.Eight patients had Ann Arbor stage Ⅰ E disease,5 had stage Ⅱ E disease,and 1 had stage Ⅲ E disease.Overall,patients were treated with surgery alone (n =4),surgery followed by radiotherapy or chemotherapy (n =5),chemotherapy plus radiotherapy (n =3),or chemotherapy alone (n =2).Results The median age at diagnosis was 55 years.The male-to-female ratio was 1 ∶ 1.33.With a median follow-up of 48.3 months,no patient died during follow-up,but 3 patients had recurrence in the lungs,mediastinal lymph nodes,and right lung and meninges at 24.5,28.5,and 36.5 months,respectively,after treatment.The 2-and 4-year progression-free survival rates were 91％ and 69％,respectively.Conclusions Primary pulmonary MALT lymphoma is indolent,and most patients show a good response to treatment.Clinical treatment should be selected according to the lesion and patient's condition.
展开▼
